Navigation Links
Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Date:7/30/2008

CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

"This patent represents an important component in the development of our intellectual property in peptide copolymers, including PI-2301," stated Thomas P. Mathers, President and CEO of Peptimmune. "The '790 patent protects what we believe may become a very important therapy for the treatment of multiple sclerosis and other autoimmune diseases."

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and eff
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...re/ -- New research has found that the availabilit...T) scanner in an emergency room can significantly ...a potentially life-saving treatment. Results of th...NSMC)-Salem Hospital in Salem, Mass., will be pres...cal Society of North America (RSNA). , , "T...
(Date:12/1/2008)...RNewswire-USNewswire/ -- A study has found that po... for imaging the breast, is not affected by either...factors that limit the effectiveness of standard m...ll be presented today at the annual meeting of the... , "The ability of PEM to detect cancer does...
(Date:12/1/2008)...irstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: ...f the world,s leading medical journals, results of... experimental compound tasimelteon (VEC-162). The...elatonin agonist tasimelteon (VEC-162) for transie... controlled multicentre trials." Results are repor...
(Date:12/1/2008)...rgeGen has announced that an oral,presentation of...d clinical,trial of TG101348 in myeloproliferativ... American Society of Hematology (ASH) Meeting. , ...:, Title: A Phase I Study of TG... JAK2-Selective Inhibitor, in Patients with,...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Helix BioPharma Announces 2411 4 Million Private Placement 7982 1Helix BioPharma Announces 2411 4 Million Private Placement 7982 2New England Peptide Names Director of Chemical Development 7977 1New England Peptide Names Director of Chemical Development 7977 2LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 1LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 2LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 3Kazak apple research key to preventing blue mold 5127 1Kazak apple research key to preventing blue mold 5127 2
...al Meeting of the American,Psychiatric Association... -- In adults with,major depressive disorder, addi...sulted in significant improvement in the primary,e...Scale (MADRS),Total Score. In this six-week, rando...the 160th Annual Meeting of the American,Psychiatr...
...ewswire/ -- Sirion Therapeutics,Inc., an ophthalm...day that it has received orphan drug designation f... anti-viral therapy,ganciclovir, for the treatmen...ently marketed by Laboratoires Thea in Europe unde... rights to,Virgan(R) for the United States from La...
Other Medicine Technology:Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2
(Date:12/2/2008)... At this year,s ASHP midyear meeting...rusted distributor of critical-care biopharmaceuti...model for supply chain integrity and demonstrate h...on to a new level. (Booth #1439) , ...,s ASHP midyear meeting, FFF Enterprises, the nati...
(Date:12/2/2008)... Marathon Health, a leading provider...s, has announced that New Balance, the athletic pr...velop, implement and manage onsite health clinics ...alance facilities in Maine , ...athon Health, a leading provider of onsite employe...
(Date:12/2/2008)... Does your over-the-phone interpreta... after you have completed the call? , ...2008 -- In the world of over-the-phone interpretat...OPI, a second over one minute can add up over the ...ding. When an organization employs an over-the-pho...
(Date:12/2/2008)... For many families, the problem with... Koch provides insight into how caregivers of agin...to the elder care experience. , ...or many families the stress of the holiday season ...t and elder care expert Esther Koch , founder of ...
Breaking Medicine News(10 mins):Health News:FFF Enterprises Unveils ‘The 8 Critical Steps to Guaranteed Channel Integrity' at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Orlando 2Health News:FFF Enterprises Unveils ‘The 8 Critical Steps to Guaranteed Channel Integrity' at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Orlando 3Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 2Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3
...troke victims to bust blood clots may help treat s... according to a study published Monday. While tre... significantly in the last 25 years, it has largel...tbite, say the authors of the article published in...
...f an unarmed man on his wedding day, the New York ...halyzer tests after such shootings. Sean Bell, a 2... girlfriend, died in a hail of 50 bullets hours be...ar. Police opened fire on Bells car outside a top...
...on for cancer patients who have to spend weeks in ...ase of Nick Gall-Tomassen, aged 31, suffering fro...on time away from the ward. His backpack holds re...t into his body through a vein in his arm. Nick sa...
... Heart Center helps explain excessive body weight ...body weight is associated with a thickening of the...mping chamber. Known to physicians as left ventric...can lead to heart failure and rhythm problems. &#...
Other Medicine News:Health News:Frostbite can Be Treated by Bloodclot Drug 2Health News:Breathalyzer Tests for Cops Involved in Shootings 2Health News:Special Backpacks Provide Much Needed Relief for Cancer Patients 2
Avant E-Z Rack Premium Low Binding 10 l Microreach Pipet Tips are accurate, contamination free, and allow quantitative transfer of your samples without relying on silicone.
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Medicine Products: